CT colonography provides new insights into interval cancers

Estimation of cancer risks due to chest radiotherapy treatment planning computed tomography (CT) simulations

The objective of our study was to determine organ doses to estimate the lifetime attributable risk (LAR) of cancer incidence related to chest tomography simulations for Radiotherapy Treatment Planning (RTTP) using patient-specific information. Patient data were used to calculate organ doses and effective dose. The effective dose (E) was calculated by two methods. First, to calculate effective dose in a standard phantom, the collected dosimetric parameters were used with the ImPACT CT Patient Dosimetry Calculator and E was calculated by applying related correction factors. Second, using the scanner-derived Dose Length Product, LARs were computed using the US National Academy of Sciences (BEIR VII) model for age- and sex-specific risks at each exposure. DLP, CTDI_vol, and scan length were 507 ± 143 mGy.cm, 11 ± 4 mGy, and 47 ± 7 cm, respectively. The effective dose was 10 ± 3 mSv using ImPACT patient dosimetry calculator software and 9 ± 2 mSv using the scanner-derived Dose Length Product. The LAR of cancer incidence for all cancers, all solid cancers and leukemia were 65 ± 29, 62 ± 27, 7 ± 2 cases per 100,000 individuals, respectively. Radiation exposure from the usage of CT for radiotherapy treatment planning (RTTP) causes non-negligible increases in lifetime attributable risk. The results of this study can be used as a guide by physicians to implement strategies based on the As Low As Reasonably Achievable (ALARA) principle that lead to a reduction dose without sacrificing diagnostic information.

Radiation Exposure Associated With Computed Tomography in Childhood and the Subsequent Risk of Cancer: A Meta-Analysis of Cohort Studies

Background:

Computed tomography (CT) is used worldwide; however, recent studies suggest that CT radiation exposure during childhood may be a risk factor for cancer, although the data are inconsistent.

Methods:

A comprehensive search of electronic databases including PubMed, SpringerLink, Embase, Cochrane Library, Elsevier/ScienceDirect, Medline, Orbis, and Web of Science databases from January 1990 to November 2018 for observational epidemiologic studies reporting associations between radiation exposure from CT in childhood and the subsequent risk of cancer was conducted. A linear model was used to explore the dose–response relationship.

Results:

Seven studies with 1180 987 children enrolled were included. The risk of later cancer was 1.32-fold higher for children exposed to CT than those without exposure. Compared to those not exposed to pediatric CT, the relative risk (RRs) were larger for the higher doses but with wider CIs (RR for 5-10 mGy: 0.90, 95% CI: 0.69-1.12; RR for 10-15 mGy: 1.02, 95% CI: 0.86-1.18; RR for >15 mGy: 1.13, 95% CI: 0.97-1.30), the leukemia risk was higher in exposed children (RR: 1.23, 95% CI: 1.10-1.36), and brain cancer risk was higher in exposed children (RR: 1.54, 95% CI: 0.84-2.45).

Conclusions:

Our analysis suggested that radiation exposure from CT during childhood is associated with a subsequently elevated risk of cancer. However, caution is needed when interpreting these results because of the heterogeneity among the studies. The findings should be confirmed in further studies with longer follow-up periods.

Positive Predictive Value for Colorectal Lesions at CT Colonography: Analysis of Factors Impacting Results in a Large Screening Cohort

OBJECTIVE. The purpose of this study is to evaluate factors affecting the positive predictive value (PPV) for detecting colorectal lesions at CT colonography (CTC), using optical colonoscopy (OC) as the reference standard for concordance. MATERIALS AND METHODS. Consecutive CTC studies from a single screening program interpreted as positive for at least one detected colorectal lesion 6 mm or larger and sent for subsequent OC were analyzed according to per-polyp and per-patient results. Univariable and multivariable analysis of multiple input factors was performed. RESULTS. Of 1650 studies (median patient age, 59.7 years; 877 men and 773 women) with 2688 total CTC-detected lesions 6 mm or larger, the overall PPVs were 88.8% (2386/2688) by polyp and 90.8% (1499/1650) by patient. The by-polyp PPV was significantly higher for polypoid (91.2%; 1793/1965) versus flat or nonpolypoid (79.4%; 459/578) lesions (p < 0.0001). Overall per-patient PPVs were 72.3% (1193/1650) for any neoplasia 6 mm or larger and 38.8% (641/1650) for advanced neoplasia. PPVs for advanced neoplasia increased by CTC Reporting and Data System category: 5.8% (45/781) for C2, 67.1% (511/762) for C3, and 79.4% (85/107) for C4. PPVs for cancer also increased by CTC Reporting and Data System category: 0% (0/781) for C2, 2.2% (17/762) for C3, and 52.3% (56/107) for C4. On multivariable regression analysis, polyp morphologic type (flat vs polypoid) and diagnostic confidence were the strongest predictors of CTC-OC concordance. CTC PPV results are somewhat underestimated because 28.8% (87/302) of CTC-OC-discordant results were categorized as likely OC false-negatives at consensus review. CONCLUSION. Concordance between CTC and OC is high for relevant colorectal polyps and masses. Unlike stool-based tests that provide only a binary positive or negative result, CTC can specify the nature of the positive findings, resulting in much greater specificity and risk stratification for patient management decisions.

Volumetric growth rates of sessile serrated adenomas/polyps observed in situ at longitudinal CT colonography

OBJECTIVE

Sessile serrated adenomas/polyps (SSA/Ps) are now recognized as potential cancer precursors, but little is known about their natural history. We assessed the in vivo growth rates of histologically proven SSA/Ps at longitudinal CT colonography (CTC) and compared results with non-advanced tubular adenomas (TAs).

METHODS

We identified a cohort of 53 patients (mean age, 54.8 ± 5.5 years; M:F, 26:27) from one center with a total of 58 SSA/Ps followed longitudinally at CTC (mean follow-up interval, 5.3 ± 1.9 years). Initial and final size measurements were determined using dedicated CTC software. Findings were compared with 141 non-advanced TAs followed at CTC (mean, 4.1 ± 2.3 years) in 113 patients (mean age, 56.8 ± 6.9 years).

RESULTS

SSA/Ps were more often flat (62% [36/58] vs. 14% [20/141], p < 0.0001) and right-sided (98% [57/58] vs. 46% [65/141], p < 0.0001) compared with TAs. Initial average diameter was greater for SSA/Ps (9.3 mm vs. 6.3 mm; p < 0.0001). Mean annual volumetric growth was + 12.7%/year for SSA/Ps vs. + 36.4%/year for TAs (p = 0.028). Using a previously defined threshold of + 20% increase in volume/year to define progression, 22% (13/58) of SSA/Ps and 41% (58/141) of TAs progressed (p = 0.014). None of the SSA/Ps had dysplasia or invasive cancer at histopathology.

CONCLUSIONS

Sessile serrated adenoma/polyps demonstrate slower growth compared with conventional non-advanced tubular adenomas, despite larger initial linear size. This less aggressive behavior may help explain the more advanced patient age for serrated pathway cancers. Furthermore, these findings could help inform future colonoscopic surveillance strategies, as current guidelines are largely restricted to expert opinion related to the absence of natural history data.

KEY POINTS

• Sessile serrated adenoma/polyps (SSA/Ps) tend to be flat, right-sided, and demonstrate slower growth compared with conventional non-advanced tubular adenomas. • This less aggressive behavior of SSA/Ps may help explain the more advanced patient age for serrated pathway cancers.